Jayson Punwani, Ph.D., joined Takeda Ventures, Inc. (TVI) in October 2017 as Investment Director. Prior to TVI, Dr. Punwani was a Senior Principal at Pappas Ventures, where he represented the firm as an observer on the Board of Directors for Balance Therapeutics, CardioDx, CoLucid (acquired by Eli Lilly), Lumena Pharmaceuticals (acquired by Shire) and OrphoMed, among others. Prior to his six years on the investment team at Pappas Ventures, he was co-manager for the University of North Carolina (UNC) Kenan-Flagler Private Equity Fund. He also worked in the Office of Technology Development at UNC-Chapel Hill, where he developed and executed commercialization and licensing strategies for biomedical technologies.
Dr. Punwani earned his M.B.A. from UNC-Chapel Hill, his Ph.D. in Biology from the University of Utah and his B.S. in Biology with a minor in Chemistry from the College of New Jersey.